Who is sponsoring NCT03672240?

NCT03672240 is sponsored by Asieris Pharmaceutical Technologies Co., Ltd..

What drugs are being tested in NCT03672240?

Interventions in NCT03672240: APL-1202.

What condition does NCT03672240 study?

NCT03672240 studies Non-Muscle Invasive Bladder Cancer (NMIBC).

Is NCT03672240 still recruiting?

NCT03672240 is currently completed. Last updated 20 July 2020.

Last reviewed 2020-07-20 · How we verify

NCT03672240: NMIBC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

Completed Phase 1, PHASE2 Last updated 20 July 2020

What this trial tests

Phase 1, PHASE2 trial testing APL-1202 in Non-Muscle Invasive Bladder Cancer (NMIBC) in 6 participants. Completed in 30 June 2020.

Timeline

30 November 2018

Primary endpoint
30 October 2019

30 June 2020

Quick facts

Lead sponsor	Asieris Pharmaceutical Technologies Co., Ltd.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	30 November 2018
Primary completion	30 October 2019
Estimated completion	30 June 2020
Sites	2 locations across United States

Drugs / interventions tested

APL-1202 — full drug profile →

Conditions studied

Non-Muscle Invasive Bladder Cancer (NMIBC) — all drugs for Non-Muscle Invasive Bladder Cancer (NMIBC) →

Sponsor

Asieris Pharmaceutical Technologies Co., Ltd.

Who can join

Adults 18 to 99, any sex, with Non-Muscle Invasive Bladder Cancer (NMIBC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Amino acid metabolism in health and disease.
Ling ZN, Jiang YF, Ru JN, Lu JH, et al · · 2023 · cited 291× · PMID 37699892 · DOI 10.1038/s41392-023-01569-3
Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review.
Nelson BE, Hong A, Jana B. · · 2021 · cited 8× · PMID 34422659 · DOI 10.3389/fonc.2021.705294
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.
Gurbani CM, Chong YL, Choo ZW, Chia D, et al · · 2025 · cited 1× · PMID 40584211 · DOI 10.1177/23523735251348842
Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review.
Soma T, Takemura K, Toide M, Ito M, et al · · 2026 · PMID 41635525 · DOI 10.1136/bmjonc-2025-000753

Verify or expand the search:

Other trials of APL-1202

Trials testing the same drug.

NCT06435039 — A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers · Phase 1 · terminated
NCT04736394 — A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Ins · Phase 3 · unknown

Other recruiting trials for Non-Muscle Invasive Bladder Cancer (NMIBC)

Currently open trials in the same condition.

NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03672240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asieris Pharmaceutical Technologies Co., Ltd.
Last refreshed: 20 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03672240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing